IDEXX Laboratories (NASDAQ:IDXX) Stock Rating Upgraded by Wall Street Zen

IDEXX Laboratories (NASDAQ:IDXX) was upgraded by research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report released on Saturday.

Other analysts also recently issued reports about the company. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. Stifel Nicolaus set a $775.00 price objective on shares of IDEXX Laboratories in a research report on Monday, November 3rd. BTIG Research dropped their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Finally, Jefferies Financial Group restated a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $777.78.

IDEXX Laboratories Stock Up 0.2%

Shares of NASDAQ IDXX opened at $644.61 on Friday. The stock has a market capitalization of $51.47 billion, a price-to-earnings ratio of 49.32, a price-to-earnings-growth ratio of 3.92 and a beta of 1.67. IDEXX Laboratories has a 52 week low of $356.14 and a 52 week high of $769.98. The firm has a 50-day moving average price of $693.74 and a 200 day moving average price of $664.06. The company has a quick ratio of 0.87, a current ratio of 1.23 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the company posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts anticipate that IDEXX Laboratories will post 11.93 EPS for the current fiscal year.

Institutional Investors Weigh In On IDEXX Laboratories

A number of institutional investors have recently bought and sold shares of IDXX. EverSource Wealth Advisors LLC grew its stake in shares of IDEXX Laboratories by 14.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 713 shares of the company’s stock valued at $482,000 after buying an additional 92 shares during the period. Americana Partners LLC boosted its holdings in IDEXX Laboratories by 228.7% in the fourth quarter. Americana Partners LLC now owns 4,520 shares of the company’s stock valued at $3,058,000 after acquiring an additional 3,145 shares during the last quarter. Lloyd Advisory Services LLC. purchased a new stake in IDEXX Laboratories during the fourth quarter valued at about $48,000. Evoke Wealth LLC increased its stake in IDEXX Laboratories by 10.7% during the fourth quarter. Evoke Wealth LLC now owns 436 shares of the company’s stock worth $295,000 after acquiring an additional 42 shares during the last quarter. Finally, Keudell Morrison Wealth Management purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth about $265,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.